Epitope spreading has been best characterized as an exacerbating factor in CD4 ⍣ T cell-dependent autoimmune disease models and is believed to occur via presentation of antigens liberated by tissue destruction initiated by CD4 ⍣ T cells specific for a primary epitope. The growing evidence that exogenous antigens can also be processed and presented by class I MHC molecules has suggested that epitope spreading could occur for CD8 ⍣ cytotoxic T lymphocyte (CTL) responses as well. In the context of anti-tumor immunity, expansion of a CTL response to include secondary epitopes could improve the efficacy of therapeutic vaccines. To determine directly whether epitope spreading can occur during an anti-tumor immune response, two defined class I MHC-binding peptides in the P815 tumor model were utilized. We observed that immunization against the single tumor peptide, P1A, followed by rejection of a P1A ⍣ tumor, subsequently yielded CTL activity and tumor protection against a P1A -tumor variant. P1A immunized mice that subsequently rejected tumor challenge developed CTL against a second defined epitope, P1E. These results indicate that, as for class II-restricted peptides in autoimmune disease, epitope spreading can occur for class I-restricted peptides during tumor rejection. A broadened CTL response may help eliminate outgrowth of antigen-negative tumor variants.
Introduction
Epitope spreading is an extension of focus during the course spreading to become manifest (3) (4) (5) (6) (7) (8) (9) (10) (11) . It is thought that an initiating self-antigen or a persistent viral epitope, presented of a specific immune response from one dominant antigenic peptide, or epitope, to include secondary epitopes distinct in MHC class II molecules on the surface of professional antigen-presenting cells (APC) residing in the target tissue, from and non-cross-reactive with the first peptide. Epitope spreading is a recognized phenomenon of autoimmune causes the activation of CD4 ϩ T cells specific for that antigen. This T cell activation results in chronic inflammation, leading responses and is believed to be an exacerbating factor in CD4 ϩ T cell-mediated autoimmune diseases. The phenomto damage of the target tissue. Tissue debris is subsequently taken up by APC which have up-regulated expression of enon has been demonstrated in murine relapsing-remitting experimental autoimmune encephaleomyelitis (EAE), Theiler's MHC class II and co-stimulatory molecules in response to inflammatory cytokines. These APC are then capable of murine encephalomyelitis virus-induced demyelineating disease and diabetes in the non-obese diabetic (NOD) mouse activating CD4 ϩ T cells specific for secondary tissue epitopes presented by the APC. The newly activated T cells then aid (1, 2) . A model has been suggested for how epitope spreading in autoimmune diseases mediated by CD4 ϩ T cells occurs in destruction of the target tissue. Due to the requirement for presentation by APC of exogen- (2) . This model is supported by direct evidence that tissue damage, TCR ligation on CD4 ϩ T cells by MHC class IIous antigen, epitope spreading has historically been thought of as a phenomenon unique to CD4 ϩ T cell responses. peptide complexes, CD40-CD40 ligand interactions and CD28-mediated co-stimulation are required for epitope However, recent data have indicated that cross-priming by APC can participate in the induction of CD8 ϩ cytotoxic Cell lines T lymphocyte (CTL) responses as well (12) (13) (14) . In particular, All cells were cultured in DMEM supplemented with 10% FCS bone marrow chimera studies in murine tumor models have and incubated at 37°C in a 8% CO 2 atmosphere. The following shown that tumor-specific CTL are predominately restricted clones of P815 were used in this study: P1.HTR, a highly to the MHC of the host rather than that of the tumor, suggesting transfectable variant of P815; P1.HTR.B7-1, a P1.HTR transthat indirect presentation by host APC is involved in the fectant expressing murine B7-1 along with a neomycin resistgeneration of tumor-specific CTL (12,13). Moreover, there is ance gene (21); P511 an azaguanine-resistant variant of P815 increasing evidence that a pathway exists whereby exogenexpressing high levels of P1A and P1E; and P1.204, a ous antigen can be presented for eventual peptide loading P815AB -variant carrying a deletion of the gene P1A (22). In onto class I MHC molecules. This phenomenon is best addition, the following cell lines were used: L1210, a DBA/2 described for dendritic cells (DC) and provides a cellular syngeneic leukemia cell line lacking expression of the known mechanism to explain the process of cross-priming (15-17).
P815 antigens; YAC-1, a murine NK-sensitive target; transfecCollectively, these data suggest that it may be possible for tants of RMA-S expressing either the H-2L d gene (RMA-S/L d ) epitope spreading to occur during a class I MHC-restricted or H-2K d gene (RMA-S/K d ) along with a neomycin resistance CTL response.
gene. All transfectants were maintained in selection drug at Because re-presentation of MHC class I-restricted tumor least every second passage. Prior to use in experiments, the antigens is known to occur, we postulated that if tumorcells were always cultured in the absence of the selection bearing hosts could initiate a CTL response against a single drug. tumor antigen, that following tumor cell damage caused by
Tumor peptides the CTL, epitope spreading might occur via a mechanism analogous to that described in CD4 ϩ T cell-mediated autoSynthetic peptides, purified by reverse-phase HPLC to Ͼ95% immune diseases. Unlike during an autoimmune response, purity, were purchased from Research Genetics (Huntsville, however, CTL epitope spreading during an anti-tumor AL). 
Cr-release assays Mice
Effector cells were diluted in duplicate in V-bottomed microtiter DBA/2J mice were obtained from the Jackson Laboratory plates and mixed with 1000 or 2000 51 Cr-labeled target cells (Bar Harbor, ME) and housed in a specific pathogen-free in a final volume of 200 µl of complete medium. Either 10 5 or facility at the University of Chicago. Female mice 8-10 weeks 2ϫ10 5 cold competitor cells (either L1210 or YAC-1) were mixed with the labeled target cells at a ratio of 30:1 before of age were used for experiments. addition of the effector cells. Supernatants were collected mice rejected challenge with P1.HTR tumor cells, while the tumor grew progressively in non-immunized controls. In conafter incubation for 4 h at 37°C and radioactivity measured using a 96-well plate counter (Packard, Meriden, CT). The trast, the P1A -variant P1.204 grew progressively in both immunized mice and in non-immunized controls, requiring percentage of specific 51 Cr release was calculated using standard methods.
sacrifice of the animals due to a large tumor burden. These results demonstrate that the P1A-specific CTL response Tumor challenges induced by specific immunization is associated with protection against a P1A ϩ but not a P1A -tumor. Between 2 and 4 weeks following the last immunization, mice were challenged by s.c. injection in the left flank with 10 6 Rejection cells by mice that had rejected P1.HTR was due to hyperactivinjection: 1 mg was given the day before and the day of ation of a non-antigen-specific effector mechanism, such as tumor challenge, and 0.5 mg was then given every 3 days NK activity. In order to determine whether P1.204 rejection was following tumor challenge.
in fact dependent on T cells, mice were depleted of T cells by treatment with a Thy1.2-specific mAb prior to and during P1.204 Results challenge (Fig. 3) . In fact, P1.204 grew progressively in these T cell-depleted mice, while the tumor was rejected by control Immunization with P1A-loaded PBMC plus IL-12 generates a mice that were not depleted of T cells and had rejected P1.HTR.
P1A-specific CTL response and specific immunity against a
These results suggest that the rejection of P1.204 is the result P1A ϩ tumor challenge of an expanded tumor-specific T cell response generated following primary rejection of P1.HTR. Female DBA/2 mice were immunized weekly in the hind footpads for 3 consecutive weeks with irradiated P1A peptideTumor-specific CTL activity is diversified following tumor loaded PBMC plus rmIL-12 as described in Methods. rejection rmIL-12 was included in the vaccination because it had been shown previously that co-administration of IL-12 was required To determine directly if the specificity of the tumor-reactive T cell response was expanded in immunized mice that had for the induction of P1A-specific CTL via P1A-pulsed cells in DBA/2 mice (19). Two weeks after the third immunization, subsequently rejected tumors, antigen-specific lytic activity of cells from these mice was measured. Spleens were harvested spleens from individual mice were stimulated in vitro in a MLTC for 5 days with irradiated P1.HTR.B7-1 cells, and the from P1A peptide-immunized mice, immunized mice that had rejected P1.HTR, and immunized mice that had rejected resulting effector cells were tested for lytic activity against P511 (P1A ϩ ) and P1.204 (P1A -). To eliminate non-specific P1.HTR and P1.204. The spleen cells were cultured in an MLTC with P1.HTR.B7-1 cells, and cytolytic activity was lytic activity, L1210 cells were used as cold targets. As shown in Fig. 1(A) , effector cells generated from P1A peptide measured against P511 and P1.204. As had been seen previously, effector cells generated from P1A peptideimmunized mice expressed high lytic activity against P511 but little against P1.204, whereas effector cells generated immunized mice expressed high lytic activity against P511 but little against P1.204 (Fig. 2) , demonstrating that the P815-from non-immunized mice demonstrated little lytic activity against either target cell. These results demonstrate that the specific CTL response in these mice was limited to P1A specificity. Effector cells generated from immunized mice that specific CTL response in immunized mice was limited to P1A.
To determine if induction of P1A-specific CTL conferred had rejected P1.HTR or from immunized mice that had rejected both P1.HTR and P1.204 also expressed high lytic specific protection against a P1A ϩ tumor, immunized mice were challenged s.c. in the left flank with P1A ϩ P1.HTR cells activity against P511 (Fig. 4) . However, unlike the immunized mice that had not received a tumor challenge, effector cells or the P1A -variant P1.204. Tumor growth was then assessed over time. As shown in Fig. 1(B) , the P1A peptide-immunized from mice that had rejected P1.HTR also expressed detect- able lytic activity against P1.204 (Fig. 4A) , and this activity irrelevant P91A peptide or RMA-S/K d pulsed with the irrelevant P198 peptide. To eliminate the contribution of NK activity, was further increased in mice that had rejected both P1.HTR and P1.204 (Fig. 4B) . Further, effector cells from mice that assays were performed in the presence of unlabeled YAC-1 cells as cold target competitors. had rejected both tumors showed decreased lytic activity against P511. The decreased P1A-specific response measAs shown in Fig. 5 , effector cells generated from nonimmunized mice exhibited little P1A-or P1E-specific lytic ured following rejection of both the P1A ϩ and P1A -tumors suggests that a shift in the tumor-specific CTL repertoire was activity. As expected, effector cells generated from P1A peptide-immunized mice lysed P1A-pulsed RMA-S/L d cells required for elimination of the P1A -tumor cells. These results suggest that during the course of tumor rejection initiated by but not P1E-pulsed RMA-S/K d cells, corresponding with the exclusive P1A-specific lysis seen previously with P511 and P1A-specific CTL, new CTL activity was generated against other antigens shared with the P1A -variant.
P1.204 cells as targets. However, effector cells generated from P1A peptide-immunized mice that had rejected both It was desirable to examine whether CTL recognizing a second defined tumor antigen epitope were induced in P1A P1.HTR and P1.204 tumor challenges gained new lytic activity specific for the P1E peptide (Fig. 5 ). In addition, the magnitude peptide-immunized mice that subsequently rejected P1.HTR and P1.204. To this end, we took advantage of the recently of the P1A-specific lysis of these effectors was modestly but reproducibly lower than that of effectors generated from P1A-identified P1E gene cloned from P815 that encodes a mutated peptide antigen presented by H-2K d (20) . Spleen cells harimmunized mice that had not been challenged with tumor. This diminution of the P1A-specific response suggests a vested from P1A peptide-immunized mice, and immunized mice that had rejected P1.HTR and P1.204, were cultured in an quantitative shift towards new CTL specificities as tumor rejection occurs. These results directly demonstrate acquisi-MLTC with P1.HTR.B7-1 and cytolytic activity was measured against RMA-S/L d or RMA-S/K d pulsed with the P1A or P1E tion of CTL specific for a secondary epitope following tumor rejection induced by effective immunization with a primary peptide respectively. To control for peptide specificity, lytic activity was also tested against RMA-S/L d pulsed with the tumor antigen epitope. 
Discussion
Epitope spreading was originally described in murine models of autoimmune disease. The expansion of T cell specificities to include multiple antigens expressed in the target tissue exacerbates autoimmune aggression and poses a substantial barrier to treatment aimed at antigen-specific tolerance (23) . The process of and the ramifications of epitope spreading have been best characterized in murine models of R-EAE and diabetes mellitus. In these models, disease development is dependent upon a CD4 ϩ T cell response and it is within these CD4 ϩ T cell populations that epitope spreading has been documented (2). The focus on CD4 ϩ T cells in the study of epitope spreading is largely related to the requirement for exogenous cellular antigen released by destroyed tissue to be presented by APC for the phenomenon to occur. Historically, exogenous antigen was thought to be processed and presented in MHC class II, but not class I molecules, disallowing We hypothesized that, following tumor cell damage inflicted the disease is induced by immunizing mice with a proteolipid protein epitope or myelin basic protein epitope, and as by CTL specific for a single tumor antigen peptide, released tumor antigen could be taken up by activated host APC that disease progresses, immune responses spread to other central nervous system antigen epitopes (1,3). We liken the could then present additional tumor antigen peptides to CD8 ϩ T cells specific for these secondary tumor antigens. The broadened CTL response observed following P815 tumor rejection induced by immunization with the single P1A peptide subsequent expansion of a tumor-specific CTL response could be beneficial to the host by providing a mechanism for to the broadened immune responses observed in EAE induced by active immunization. eliminating antigen-loss tumor cell variants that have been shown to emerge under immune pressure (24, 25) .
Although the evidence that cross-priming through host APC is a dominant pathway for induction of class I MHC-restricted Our present study suggests that the phenomenon of epitope spreading is not limited to CD4 ϩ T cell responses. Immunizaanti-tumor CTL suggests that epitope spreading is likely to occur via host APC as well, this has yet to be demonstrated tion with P1A peptide followed by tumor rejection clearly led to CTL activity against a P1A -tumor. This population of CTL directly. It is conceivable that the presence of P1A-specific CTL generates a microenvironment that facilitates direct antiincluded cells that recognized the unrelated antigen P1E. Since this epitope was not included in the vaccine and is a gen presentation by tumor cells. Further experiments will be required to distinguish whether the epitope spreading we mutated peptide not presented in normal tissues, the source of P1E antigen must have been the tumor cell challenge.
observe is the result of increased direct antigen presentation by tumor cells or increased presentation of released tumor Epitope spreading has been characterized both in autoimmune responses generated spontaneously as well as in antigens by host APC. In addition, it will be of interest to determine the requirement for co-stimulatory molecules and those generated by active immunization. One of the best characterized autoimmune disease models which has been other factors for priming against secondary epitopes recognized by CD8 ϩ T cells. used to study epitope spreading is murine EAE. In this model, Previous studies had suggested that selection of antigention of a CTL response against, and the elimination of, tumor cell variants that have lost expression of antigen. However, it loss variants of P815 cells under immune pressure in vivo was not an uncommon event (22). P1A expression was is unlikely that this mechanism will be sufficient to eliminate large numbers of antigen-negative tumor cells. The time commonly lost in progressively growing tumors. However, in our current studies using vaccination with P1A peptide-pulsed required for epitope spreading to occur may be too prolonged to keep up with the growth rate of abundant tumor cells APC ϩ rmIL-12, selection for P1A -variants has not been seen. This is likely explained by the epitope spreading process lacking expression of the tumor antigen. Indeed, preliminary experiments have revealed that a 1:1 mixture of P1A ϩ and that follows immunization. It is conceivable that the IL-12 included during vaccination promotes a particularly effective P1A -tumor cells grows progressively in P1A-immunized mice (M. Markiewicz, unpublished observation). However, the immune response that favors re-presentation of antigens from destroyed tumor tissue.
potential for CTL epitope spreading suggests that if tumorbearing individuals can be induced to generate a CTL The occurrence of epitope spreading following CTLdependent tumor damage suggests a method for the generaresponse against antigen expressed by the majority of their 
